Re-energizing the Development of Pain Therapeutics in Light of the Opioid Epidemic

Phil Skolnick; Nora D Volkow

doi:10.1016/j.neuron.2016.09.051

Re-energizing the Development of Pain Therapeutics in Light of the Opioid Epidemic

Neuron. 2016 Oct 19;92(2):294-297. doi: 10.1016/j.neuron.2016.09.051.

Authors

Phil Skolnick¹, Nora D Volkow²

Affiliations

¹ Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA.
² Office of the Director, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: nvolkow@nida.nih.gov.

PMID: 27764663
DOI: 10.1016/j.neuron.2016.09.051

Abstract

Limited options for treating moderate-severe pain led to an overreliance on opioids and the current opioid epidemic. Addressing the factors contributing to a dearth of effective alternatives and re-energizing the development of pain therapeutics is necessary to quell this epidemic.

Published by Elsevier Inc.

MeSH terms

Acute Pain / drug therapy
Analgesics / therapeutic use*
Analgesics, Opioid / therapeutic use
Chronic Pain / drug therapy*
Drug Discovery*
Epidemics*
Humans
Opioid-Related Disorders / epidemiology*
Pain Management
Phenyl Ethers / therapeutic use
Pregabalin / therapeutic use
Proline / analogs & derivatives
Proline / therapeutic use

Substances

Analgesics
Analgesics, Opioid
Phenyl Ethers
Pregabalin
Proline
vixotrigine